Lower Costs, More Cures Act of 2019

3.0.0 1499 2022-11-01T17:03:25Z 2022-11-01T17:03:25Z House HR 2019-03-05 116 [Congressional Record Volume 165, Number 39 (Tuesday, March 5, 2019)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. RUSH:H.R. 1499.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8[Page H2368]]]> hsju00 Judiciary Committee House Standing hsju05 Administrative State, Regulatory Reform, and Antitrust Subcommittee Referred to 2019-04-08T20:38:28Z Discharged from 2019-05-10T13:43:36Z Referred to 2019-03-05T17:04:25Z hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Reported by 2019-03-27T16:25:08Z Markup by 2019-03-27T16:25:00Z Referred to 2019-03-06T17:15:38Z Reported by 2019-05-10T13:42:57Z Markup by 2019-04-03T20:01:18Z Referred to 2019-03-05T17:04:20Z H. Rept. 116-52 Lower Costs, More Cures Act of 2019 116 19 HR 2019-12-19 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Related bill CRS Strengthening Health Care and Lowering Prescription Drug Costs Act 116 987 HR 2019-05-20 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act 116 2700 HR 2019-06-26 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Related bill CRS 2019-05-10 Placed on the Union Calendar, Calendar No. 30. Calendars H12410 2 House floor actions U00030 2019-05-10 Committee on the Judiciary discharged. Discharge H12300 2 House floor actions hsju00 Judiciary Committee 2019-05-10 Committee on the Judiciary discharged. Committee 5500 9 Library of Congress hsju00 Judiciary Committee 2019-05-10 Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-52, Part I. Committee H12200 2 House floor actions hsif00 Energy and Commerce Committee 2019-05-10 Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-52, Part I. Committee 5000 9 Library of Congress hsif00 Energy and Commerce Committee 2019-04-08 hsju05 Administrative State, Regulatory Reform, and Antitrust Subcommittee 1 House committee actions Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. Committee 2019-04-03 hsif00 Energy and Commerce Committee 1 House committee actions Ordered to be Reported (Amended) by Voice Vote. Committee 2019-04-03 hsif00 Energy and Commerce Committee 1 House committee actions Committee Consideration and Mark-up Session Held. Committee 2019-03-27 hsif14 Health Subcommittee 1 House committee actions Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote . Committee 2019-03-27 hsif14 Health Subcommittee 1 House committee actions Subcommittee Consideration and Mark-up Session Held. Committee 2019-03-06 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2019-03-05 Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsju00 Judiciary Committee 2019-03-05 Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2019-03-05 Introduced in House IntroReferral Intro-H 9 Library of Congress 2019-03-05 Introduced in House IntroReferral 1000 9 Library of Congress R000515 Rep. Rush, Bobby L. [D-IL-1] BOBBY RUSH D IL L. 1 N P000034 Rep. Pallone, Frank, Jr. [D-NJ-6] FRANK PALLONE D NJ 6 2019-03-26 False R000599 Rep. Ruiz, Raul [D-CA-36] Raul Ruiz D CA 36 2019-03-26 False D000624 Rep. Dingell, Debbie [D-MI-12] Debbie Dingell D MI 12 2019-03-26 False C001119 Rep. Craig, Angie [D-MN-2] Angie Craig D MN 2 2019-03-26 False E000215 Rep. Eshoo, Anna G. [D-CA-18] ANNA ESHOO D CA G. 18 2019-03-26 False K000379 Rep. Kennedy, Joseph P., III [D-MA-4] Joseph Kennedy D MA P. 4 2019-03-26 False M001163 Rep. Matsui, Doris O. [D-CA-6] Doris Matsui D CA O. 6 2019-03-27 False V000133 Rep. Van Drew, Jefferson [D-NJ-2] Jefferson Van Drew D NJ 2 2019-04-01 False C001067 Rep. Clarke, Yvette D. [D-NY-9] Yvette Clarke D NY D. 9 2019-04-01 False K000389 Rep. Khanna, Ro [D-CA-17] Ro Khanna D CA 17 2019-04-03 False S001145 Rep. Schakowsky, Janice D. [D-IL-9] JANICE SCHAKOWSKY D IL D. 9 2019-04-04 False P000614 Rep. Pappas, Chris [D-NH-1] Chris Pappas D NH 1 2019-04-04 False C001068 Rep. Cohen, Steve [D-TN-9] Steve Cohen D TN 9 2019-04-08 False W000800 Rep. Welch, Peter [D-VT-At Large] Peter Welch D VT 0 2019-04-08 False L000557 Rep. Larson, John B. [D-CT-1] JOHN LARSON D CT B. 1 2019-04-09 False H000324 Rep. Hastings, Alcee L. [D-FL-20] ALCEE HASTINGS D FL L. 20 2019-04-09 False N000191 Rep. Neguse, Joe [D-CO-2] Joe Neguse D CO 2 2019-04-15 False F000467 Rep. Finkenauer, Abby [D-IA-1] Abby Finkenauer D IA 1 2019-04-15 False C001055 Rep. Case, Ed [D-HI-1] Ed Case D HI 1 2019-04-15 False Q000023 Rep. Quigley, Mike [D-IL-5] Mike Quigley D IL 5 2019-04-25 False W000826 Rep. Wild, Susan [D-PA-7] Susan Wild D PA 7 2019-04-25 False L000559 Rep. Langevin, James R. [D-RI-2] JAMES LANGEVIN D RI R. 2 2019-04-25 False C000754 Rep. Cooper, Jim [D-TN-5] JAMES COOPER D TN H. 5 2019-04-25 False R000606 Rep. Raskin, Jamie [D-MD-8] Jamie Raskin D MD 8 2019-04-29 False S001157 Rep. Scott, David [D-GA-13] David Scott D GA 13 2019-04-29 False M001207 Rep. Mucarsel-Powell, Debbie [D-FL-26] Debbie Mucarsel-Powell D FL 26 2019-04-29 False T000193 Rep. Thompson, Bennie G. [D-MS-2] BENNIE THOMPSON D MS 2 2019-05-01 False S001215 Rep. Stevens, Haley M. [D-MI-11] Haley Stevens D MI M. 11 2019-05-01 False C001123 Rep. Cisneros, Gilbert Ray, Jr. [D-CA-39] Gilbert Cisneros D CA Ray 39 2019-05-01 False K000385 Rep. Kelly, Robin L. [D-IL-2] Robin Kelly D IL L. 2 2019-05-07 False C001117 Rep. Casten, Sean [D-IL-6] Sean Casten D IL 6 2019-05-07 False H001085 Rep. Houlahan, Chrissy [D-PA-6] Chrissy Houlahan D PA 6 2019-05-07 False C001072 Rep. Carson, Andre [D-IN-7] Andre Carson D IN 7 2019-05-07 False C001112 Rep. Carbajal, Salud O. [D-CA-24] Salud Carbajal D CA O. 24 2019-05-07 False D000629 Rep. Davids, Sharice [D-KS-3] Sharice Davids D KS 3 2019-05-07 False S000510 Rep. Smith, Adam [D-WA-9] ADAM SMITH D WA 9 2019-05-09 False C001078 Rep. Connolly, Gerald E. [D-VA-11] Gerald Connolly D VA E. 11 2019-05-09 False U000040 Rep. Underwood, Lauren [D-IL-14] Lauren Underwood D IL 14 2019-05-09 False 2019-04-30T21:28:00Z H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 https://www.cbo.gov/publication/55183 As ordered reported by the House Committee on Energy and Commerce on April 3, 2019 Health Administrative law and regulatory procedures Civil actions and liability Competition and antitrust Consumer affairs Drug safety, medical device, and laboratory regulation Federal Trade Commission (FTC) Intellectual property Judicial review and appeals Licensing and registrations Prescription drugs Health

00 2019-03-05 Introduced in House 2021-09-12T15:14:48Z Protecting Consumer Access to Generic Drugs Act of 2019

This bill prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product.

Specifically, such an agreement shall, with some exceptions, be a violation of the bill if the filer of a subsequent application to market a drug or biological product receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the subsequent drug or biological product. (Typically, a subsequent application seeks to market a generic or biosimilar version of a patented drug or biological product.)

Penalties for violations of the bill include civil penalties and loss of the 180-day exclusivity period for a generic drug. The Federal Trade Commission (FTC) shall have exclusive authority to litigate to enforce the bill.

When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains (1) the complete agreement; and (2) any agreements related to the main agreement, including descriptions of any oral agreements or representations.

]]>

08 2019-05-10 Reported to House, Part I 2021-09-12T15:17:17Z Protecting Consumer Access to Generic Drugs Act of 2019

]]>

Protecting Consumer Access to Generic Drugs Act of 2019 Display Title Protecting Consumer Access to Generic Drugs Act of 2019 Official Title as Introduced To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. Reported in House RH Short Title(s) as Reported to House Protecting Consumer Access to Generic Drugs Act of 2019 H House Reported in House RH Short Title(s) as Introduced Protecting Consumer Access to Generic Drugs Act of 2019 Introduced in House IH Reported in House 2019-05-10T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr1499rh/xml/BILLS-116hr1499rh.xml Introduced in House 2019-03-05T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr1499ih/xml/BILLS-116hr1499ih.xml 2019-05-10 Placed on the Union Calendar, Calendar No. 30. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.